

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (original) An extended release composition comprising as active compound Venlafaxine Hydrochloride, in which Venlafaxine Hydrochloride is coated on a non pareil inert core, which coated core is then coated with a polymeric layer which enables the controlled release of the Venlafaxine Hydrochloride.

2. (original) A composition according to claim 1, wherein the composition comprises 30-60% of Venlafaxine Hydrochloride per weight of the total dosage form.

3. (currently amended) A composition according to 1 ~~ex-2~~, wherein the Venlafaxine Hydrochloride is suitably connected to a binder.

4. (currently amended) A composition according to claim 3, wherein the binder is selected ~~among~~ from the group consisting of polyvinyl pyrrolidone-(povidone), hydroxypropylcellulose and hydroxypropylmethylcellulose.

5. (currently amended) A composition according to claim ~~3 or 4~~, wherein the composition comprises 0.5%-10% of the binder per weight of the total dosage form.

6. (currently amended) A composition according to ~~any of claims 1 to~~ claim 5, wherein the non pareil inert core is an inert sugar core, or a microcrystalline cellulose core ~~or the like~~.

7. (currently amended) A composition according to ~~any of claims 1 to~~ claim 6, which comprises 30-60% of the core per weight of the total dosage form.

8. (currently amended) A composition according to ~~any of claims 1 to~~ claim 7, wherein the core is coated with an isolating/protecting/separating layer.

9. (currently amended) A composition according to claim 8, wherein the isolating layer is composed of at least one polymer ~~polymers such as selected from the group~~ consisting of polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline, cellulose, carrageenan, and GMS.

10. (currently amended) A composition according to claim ~~8 or 9~~, wherein the isolating layer ~~is comprised of~~

comprises 0.5-10% of the isolating layer per weight of the weight of the total dosage form.

11. (currently amended) A composition according to ~~any of claims 1 to~~ claim 10, being coated with an additional polymeric layer.

12. (currently amended) A composition according to claim 11, wherein said additional polymeric layer is composed, ~~e.g.~~ of a hydrophobic polymer mixed with an appropriate hydrophobic or hydrophilic plasticizer.

13. (currently amended) A composition according to claim 12, wherein said coating ~~polymers~~ polymer are selected ~~among from the group consisting of Eudragit,~~ and a cellulose derivative, ~~derivatives such as hydroxypropylmethylecellulose, ethyl cellulose, cellulose acetate and their~~ said plasticizer plasticizers are is selected among from the group consisting of castor oil, dibutyl sebacate, glyceryl monostearate, diethyl phalate, glyceryl trihepthanoate, and triethyl citrate.

14. (currently amended) A composition according to ~~any of claims 12 or~~ claim 13, which comprises 2-15% of the hydrophobic polymer per weight of the total dosage form; and

0.1-2% per weight of the hydrophobic plasticizer per weight of the total dosage form.

15. (new) A composition according to 2, wherein the Venlaxfaxine Hydrochloride is suitably mixed with a binder.

16. (new) A composition according to claim 15, wherein the binder is selected from the group consisting of polyvinyl pyrrolidone, hydroxypropylcellulose and hydroxypropylmethylcellulose.

17. (new) A composition according to claim 16, wherein the composition comprises 0.5%-10% of the binder per weight of the total dosage form.

18. (new) A composition according to claim 3, wherein the composition comprises 0.5%-10% of the binder per weight of the total dosage form.

19. (new) A composition according to claim 1, wherein the non pareil inert core comprises inert sugar or microcrystalline cellulose.

20. (new) A composition according to claim 1, which comprises 30-60% of the core per weight of the total dosage form.

21. (new) A composition according to claim 1, wherein the core is coated with a layer providing at least one function of isolating, protecting and separating.

22. (new) A composition according to claim 21, wherein the layer providing at least one function of isolating, protecting and separating is composed of a polymer selected from the group consisting of polyvinylpyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, microcrystalline, cellulose, carrageenan, and GMS.

23. (new) A composition according to claim 8, wherein the isolating layer comprises 0.5-10% of the weight of the total dosage form.

24. (new) A composition according to claim 1, coated with an additional polymeric layer.

25. (new) A composition according to claim 24, wherein said additional polymeric layer is composed of a hydrophobic polymer mixed with an appropriate hydrophobic or hydrophilic plasticizer.

26. (new) A composition according to claim 25, wherein said hydrophobic polymer is Eudragit or a cellulose derivative, and said plasticizer is selected from the group consisting of castor oil, dibutyl sebacate, glyceryl

monostearate, diethyl phalate, glyceryl trihepthanoate, and triethyl citrate.

27. (new) A composition according to claim 26, which comprises 2-15% of the hydrophobic polymer per weight of the total dosage form; and 0.1-2% per weight of the hydrophobic plasticizer per weight of the total dosage form.

28. (new) A composition according to claim 12, which comprises 2-15% of the hydrophobic polymer per weight of the total dosage form; and 0.1-2% per weight of the hydrophobic plasticizer per weight of the total dosage form.